Invest-NL Invests €72 Million in ViCentra for Global Expansion
Utrecht, Wednesday, 3 September 2025.
Invest-NL’s €72 million investment in ViCentra, the developer of the Kaleido 2 insulin pump, marks one of the largest medtech investments in the Netherlands this year, supporting global scaling.
A Landmark Investment in Medtech
Invest-NL’s recent investment of €72 million in ViCentra is a significant milestone in the medtech sector, particularly in the Netherlands. This investment, one of the largest of its kind this year, underscores the confidence in ViCentra’s potential to revolutionize diabetes care with its Kaleido 2 insulin pump [1].
The Kaleido 2: A Game-Changer in Diabetes Management
ViCentra, a Netherlands-based company, has developed the Kaleido 2 insulin patch pump, recognized as the world’s smallest, lightest, and only lifestyle-oriented insulin pump. The Kaleido 2 is designed to integrate seamlessly into the user’s life, offering customizable aluminum shells and compatibility with advanced insulin delivery algorithms and continuous glucose monitoring systems [2][3].
Expanding Horizons: Global Scaling Strategy
With this new funding, ViCentra plans to scale up manufacturing and expand its market presence across Europe and the United States. The company’s strategy involves enhancing its production capabilities and preparing for regulatory submissions to both the European MDR and the US FDA [3][4]. The company’s CEO, Tom Arnold, expressed that this infusion of capital will enable ViCentra to meet the growing demand for its innovative products and fast-track its entry into the US market [3].
Impact on Diabetes Care
The Kaleido 2 insulin pump is poised to have a significant impact on the quality of life for individuals with diabetes by providing a more user-friendly and aesthetically pleasing alternative to traditional insulin pumps. As the global diabetes management market continues to grow, innovations like the Kaleido 2 are crucial in addressing the increasing demand for reliable and effective treatment options [5].